JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital
Prueksaritanond, Nisa; Cheanpracha, Patchara; Yanaranop, Marut;
  PDF(new window)
 Abstract
Background: Although there are no biomarkers that are routinely used in endometrial cancer (EC) management, many studies have found that serum human epididymis protein 4 (HE4) is superior to cancer antigen 125 (CA125) in the detection of EC. The correlation of HE4 with two prognostic factors for EC, primary tumor diameter (PTD) and depth of myometrial invasion (DMI) may be useful in identifying EC patients at high risk of lymphatic dissemination. Objective: To evaluate the correlation of serum HE4 with PTD and DMI in patients with EC. Materials and Methods: A cross-sectional study was conducted on 70 EC patients who were scheduled for elective surgery at Rajavithi Hospital between 1st September 2013 and 30th May 2014. Preoperative serum levels of HE4 and CA125 were investigated, and then gross measurement of PTD was taken and postoperative pathologic slides were reviewed for DMI including histologic types, grading and staging. Results: Preoperative serum HE4 levels were strongly correlated with PTD (r
 Keywords
Endometrial cancer;human epididymis protein 4;CA125;primary tumor diameter;myometrial invasion;
 Language
English
 Cited by
1.
Discovery of biomarkers for endometrial cancer: current status and prospects, Expert Review of Molecular Diagnostics, 2016, 16, 12, 1315  crossref(new windwow)
2.
HE4-test of urine and body fluids for diagnosis of gynecologic cancer, Expert Review of Molecular Diagnostics, 2017, 17, 3, 239  crossref(new windwow)
 References
1.
Ali A, Black D, Soslow RA (2007). Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol, 26, 115-23. crossref(new window)

2.
Angioli R, Plotti F, Capriglione S, et al (2013). The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol, 34, 571-6. crossref(new window)

3.
Antonsen SL, Hogdall E, Christensen IJ, et al (2013). HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand, 92, 1313-22. crossref(new window)

4.
Bignotti E, Ragnoli M, Zanotti L, et al (2011). Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer, 104, 1418-25. crossref(new window)

5.
Bolstad N, Oijordsbakken M, Nustad K, et al (2012). Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol, 33, 141-8. crossref(new window)

6.
Brennan DJ, Hackethal A, Metcalf AM, et al (2014). Serum HE4 as a prognostic marker in endometrial cancer--a population based study. Gynecol Oncol, 132, 159-65. crossref(new window)

7.
Cancer in Thailand (2010). Bangkok, Ministry of public health.

8.
Creasman WT, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95, 105-43. crossref(new window)

9.
Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9. crossref(new window)

10.
Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. crossref(new window)

11.
Jhang H, Chuang L, Visintainer P, et al (2003). CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol, 188, 1195-7. crossref(new window)

12.
Kalogera E, Scholler N, Powless C, et al (2012). Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol, 124, 270-5. crossref(new window)

13.
Mariani A, Dowdy SC, Cliby WA, et al (2008). Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol, 109, 11-8. crossref(new window)

14.
Mariani A, Webb MJ, Keeney GL, et al (2000). Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol, 182, 1506-19. crossref(new window)

15.
Moore RG, Brown AK, Miller MC, et al (2008). Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol, 110, 196-201. crossref(new window)

16.
Moore RG, Miller CM, Brown AK, et al (2011). Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer, 21, 1185-90.

17.
Movahedi-Lankarani S, Gilks C, Soslow R, et al (2009). Protocol for the examination of specimens from patients with carcinoma of the endometrium. college of american pathologists (CAP).

18.
Mutz-Dehbalaie I, Egle D, Fessler S, et al (2012). HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol, 126, 186-91. crossref(new window)

19.
Powell JL, Hill KA, Shiro BC, et al (2005). Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med, 50, 585-90.

20.
Takeshima N, Shimizu Y, Umezawa S, et al (1994). Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol, 54, 321-6. crossref(new window)

21.
Trovik J, Mauland KK, Werner HM, Wik E, et al (2012). Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecol Oncol, 125, 381-7. crossref(new window)

22.
Vargas R, Rauh-Hain JA, Clemmer J, et al (2014). Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol, 133, 216-20. crossref(new window)

23.
Youden WJ (1950). Index for rating diagnostic tests. Cancer, 3, 32-5. crossref(new window)